DMPK
Assets acting on this target.
- Class
- AAV gene therapy
By indication
Related mechanisms
DMPK drugs compared
2 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Delpacibart etedesiran | Novartis | antibody-oligonucleotide conjugate (siRNA) | Phase 3 | Phase 3 in Myotonic Dystrophy Type 1 |
| SAR446268 | Sanofi | gene therapy (AAV) | Phase 1/2 | Phase 1/2 in Myotonic Dystrophy Type 1 |